Barclays PLC started coverage on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a research note released on Wednesday, September 6th, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $55.00 target price on the biopharmaceutical company’s stock.
Other equities research analysts have also issued reports about the stock. Vetr upgraded shares of Juno Therapeutics to a buy rating in a research report on Tuesday, May 23rd. Wedbush reiterated a neutral rating and issued a $24.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, June 6th. Wells Fargo & Company restated an outperform rating and issued a $54.00 target price (up from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. BidaskClub upgraded shares of Juno Therapeutics from a hold rating to a buy rating in a report on Tuesday, June 20th. Finally, Zacks Investment Research upgraded shares of Juno Therapeutics from a strong sell rating to a hold rating in a report on Wednesday, July 5th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company. Juno Therapeutics presently has an average rating of Hold and an average target price of $34.88.
Juno Therapeutics (JUNO) opened at 44.30 on Wednesday. The stock’s market capitalization is $4.65 billion. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $47.00. The stock has a 50 day moving average of $34.04 and a 200 day moving average of $27.13.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same period last year, the company earned ($0.64) earnings per share. The business’s revenue for the quarter was down 22.8% compared to the same quarter last year. On average, analysts expect that Juno Therapeutics will post ($3.12) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://baseballnewssource.com/markets/barclays-plc-initiates-coverage-on-juno-therapeutics-inc-juno/1616491.html.
In other news, EVP Robert Azelby sold 12,850 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $44.95, for a total transaction of $577,607.50. Following the completion of the transaction, the executive vice president now owns 37,439 shares of the company’s stock, valued at approximately $1,682,883.05. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,119,219 shares of company stock valued at $220,455,844. Corporate insiders own 15.26% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of JUNO. Teachers Advisors LLC increased its stake in shares of Juno Therapeutics by 12.3% during the 4th quarter. Teachers Advisors LLC now owns 60,834 shares of the biopharmaceutical company’s stock valued at $1,147,000 after acquiring an additional 6,643 shares during the last quarter. Nisa Investment Advisors LLC acquired a new position in shares of Juno Therapeutics during the 1st quarter valued at about $200,000. Wells Fargo & Company MN increased its stake in shares of Juno Therapeutics by 238.4% during the 1st quarter. Wells Fargo & Company MN now owns 121,392 shares of the biopharmaceutical company’s stock valued at $2,693,000 after acquiring an additional 85,516 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in shares of Juno Therapeutics by 111.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 94,400 shares of the biopharmaceutical company’s stock valued at $2,095,000 after acquiring an additional 49,700 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in shares of Juno Therapeutics by 80.5% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 3,800 shares during the last quarter. 70.76% of the stock is owned by institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.